Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant effects on gastric function in healthy volunteers
NCT02989467Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gastroparesis and functional dyspepsia (FD) comparing Aprepitant with Placebo (2 arms). Primary endpoints: Gastric Emptying Half-Time of Solids as Measured by Scintigraphy at Day 3, Satiation Expressed as Volume to Fullness at Day 4 and 3 more. Started Jan 2017; status: completed.
02
Drugs
aprepitant
03
Conditions
gastroparesisfunctional dyspepsia (FD)
Beyond the preview
Go deeper on NCT02989467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989467.